21 completed, 4 unknown, 2 terminated, 2 withdrawn. 31 Phase 4.
By phase and status
Follow Primary Immunodeficiency Diseases: new trials by email Literature Review of Primary Immunodeficiency Diseases trials Research Report on Primary Immunodeficiency Diseases
Trials (filtered) newest first · largest first
All 31 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study of TAK-664 in People With Primary Immunodeficiency Diseases Who Have Not Yet Been Treated With Immunoglobulins
TAK-664 - Primary Immunodeficiency Diseases (PID) | Phase 4 | Not yet recruiting | 9 | 2026-11-01 | 2026-09-08 |
Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL)
KVD900 600 mg - Hereditary Angioedema | Phase 4 | Recruiting | 100 | 2026-08-17 | 2026-09-17 |
An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)
IgPro - Primary Immunodeficiency | Phase 4 | Completed | 8 | 2025-07-15 | 2026-07-16 |
Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab
Garadacimab - Hereditary Angioedema | Phase 4 | Completed | 18 | 2025-04-28 | 2026-07-23 |
A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema
Icatibant Injection (Icanticure®) - Bradykinin-mediated Angioedema, Hereditary Angioedema (HAE) | Phase 4 | Completed | 5 | 2024-09-27 | 2025-12-18 |
An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)
Asceniv™ - Primary Immune Deficiency | Phase 4 | Unknown | 12 | 2022-09-01 | 2022-09-16 |
Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age
Trumenba - Meningococcal Vaccine | Phase 4 | Completed | 53 | 2021-08-18 | 2024-10-16 |
A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency
IGSC 20% - Primary Immunodeficiency | Phase 4 | Completed | 33 | 2020-11-24 | 2023-09-29 |
Retroviral Insertion Site Methodology Study
Strimvelis - Immune System Diseases | Phase 4 | Withdrawn | | 2020-06-25 | 2024-01-29 |
Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment
16,5% Cutaquig - Primary Immunodeficiency Disease, Secondary Immunodeficiency | Phase 4 | Unknown | 30 | 2018-09-19 | 2020-03-04 |
Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest)
Ruconest - Hereditary Angioedema | Phase 4 | Completed | 5 | 2018-08-14 | 2024-11-15 |
A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions
C1-esterase inhibitor [recombinant] (C1-INH-R) - CVI - Common Variable Immunodeficiency | Phase 4 | Completed | 20 | 2018-06-13 | 2021-02-15 |
Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects
HYQVIA, KIOVIG, Cuvitru - Primary Immunodeficiency Diseases (PID) | Phase 4 | Completed | 42 | 2017-05-30 | 2023-01-11 |
Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
IgPro20 - Primary Immunodeficiency | Phase 4 | Completed | 49 | 2017-02-01 | 2020-03-25 |
C1-inhibitor in Allergic ASThma Patients
C1-inhibitor, Saline, Antibiotics - Asthma | Phase 4 | Terminated | 37 | 2016-11-16 | 2020-06-24 |
IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia
IgHy10 - Primary Immunodeficiency | Phase 4 | Completed | 22 | 2016-11-11 | 2019-06-25 |
Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone
Metformin, Pioglitazone - Ataxia-Telangiectasia | Phase 4 | Completed | 27 | 2016-09-29 | 2017-12-04 |
Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules
Subcutaneous Immune Globulin (Human) (Hizentra) - Primary Immune Deficiency, Secondary Immune Deficiency | Phase 4 | Completed | 26 | 2016-03-15 | 2018-02-26 |
A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push
Chrono Super PID then Generic Syringe-Gammanorm, Generic Syringe then Chrono Super PID-Gammanorm - Primary Immunodeficiency | Phase 4 | Completed | 30 | 2015-07-29 | 2019-04-09 |
Diagnostic Immunization With Rabies Vaccine in Patients With PID
Verorab® (PVRV; Purified Vero Cell Vaccine) - Primary Immunodeficiency | Phase 4 | Unknown | 40 | 2015-04-01 | 2015-07-07 |
Showing 20 of 31. Sign in to see all of them.
Narrower conditions
Angioedemas, Hereditary (10) · Bruton type agammaglobulinemia (3) · Common Variable Immunodeficiency (3) · Ataxia Telangiectasia (2) · Hyper-IgM Immunodeficiency Syndrome (2) · Immune System Diseases (2) · Wiskott-Aldrich Syndrome (2) · Agammaglobulinemia (1) · Anemia, Sickle Cell (1) · Angioedema (1) · Asthma (1) · Bacterial Infections (1) · Drug-Related Side Effects and Adverse Reactions (1) · Failure to Thrive (1)
Broader conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (31) · Genetic Diseases, Inborn (30) · Immunologic Deficiency Syndromes (30) · Immune System Diseases (29) · Cardiovascular Diseases (12) · Vascular Diseases (12) · Hereditary Complement Deficiency Diseases (10) · Hypersensitivity (10) · Hypersensitivity, Immediate (10) · Skin Diseases (10) · Skin Diseases, Vascular (10) · Skin and Connective Tissue Diseases (10) · Urticaria (10) · Angioedema (9)
Interventions
Hizentra (5) · gamma-Globulins (5) · Complement C1 Inhibitor Protein (3) · SERPING1 protein, human (2) · icatibant (2) · Anti-Bacterial Agents (1) · Caprylates (1) · Ciprofloxacin (1) · Clonidine (1) · Complement C1 (1) · Estradiol (1) · Fluid Therapy (1) · Growth Hormone (1) · Heptavalent Pneumococcal Conjugate Vaccine (1) · Human Growth Hormone (1)
Sponsors
CSL Behring (5) · Grifols Therapeutics LLC (2) · Octapharma (2) · ADMA Biologics, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Baxalta now part of Shire (1) · Bernstein Clinical Research Center (1) · Bio Products Laboratory (1) · Chulalongkorn University (1) · Fondazione Telethon (1) · IMMUNOe Research Centers (1) · Instituto Grifols, S.A. (1) · Johann Wolfgang Goethe University Hospital (1) · KalVista Pharmaceuticals, Ltd. (1) · Massachusetts General Hospital (1)
Countries
United States (14) · Canada (5) · France (4) · Germany (4) · United Kingdom (3) · Czechia (2) · Italy (2) · Australia (1) · Chile (1) · Denmark (1) · Greece (1) · Hungary (1) · Israel (1) · Netherlands (1) · Poland (1)
Top investigators
Aleena Banerji, M.D. (1) · Boris Bienvenu, MD (1) · Elie Haddad, MD (1) · Eric Hachulla, MD, PhD (1) · Ewan Pearson, MD PhD (1) · Fondazione Telethon (1) · Gulbu Uzel, M.D. (1) · Isaac Melamed, MD (1) · Jonathan Bernstein, MD (1) · Juthaporn Cowan, MD, PhD, FRCPC (1) · Klaus Warnatz, MD (1) · Mark Ballow, MD (1) · Michael Borte, MD (1)
Results publications
PMID 21932110, PMID 27140403, PMID 27342758, PMID 29503044, PMID 29855752, PMID 31109849, PMID 33025378, PMID 33409867, PMID 33737935, PMID 34303860, PMID 36818468, PMID 39289739
NIH funding
2016 (3), 2015 (1), 2018 (1)